Clinical trial · Observational
Immune Profiling for Cancer Immunotherapy Response
NCT06116032CI-TRIAL-00099054recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Cancer | Liquid Tumor | ALIAS | 0.90 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Tumor, Solid | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Methylation Cytometry | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Standard of Care Checkpoint
- description
- Patients receiving standard of care FDA approved immunotherapy
- interventionNames
- Diagnostic Test: Methylation Cytometry
- label
- Bone Marrow Transplant
- description
- Patients undergoing transplant for hematologic malignancy
- interventionNames
- Diagnostic Test: Methylation Cytometry
- label
- CAR T
- description
- Patients undergoing CAR T therapy
- interventionNames
- Diagnostic Test: Methylation Cytometry
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy). * Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included). Exclusion Criteria: * Pregnant women/fetuses/neonates * Prisoners * Decision-impaired individuals
References
Publications (0)
Data not yet available
No reference posted for this study.